Nippon Shinyaku Co.,Ltd.

4516

TSE PrimePharmaceuticals

¥ -

You can review earnings summary, quarterly trends, full-year progress, and detailed income statement data.

descriptionIncome Statement (PL) Summary

Updated: 2026-08-06FY2027 Q1

Revenue

1802.9100M JPY

YoY +12.2%

Operating Income

123.1100M JPY

YoY +22.1%

Net Income

315.8100M JPY

YoY +3.4%

EPS

150.0JPY

YoY +22.4%

Performance Trend

Revenue, operating income and net income trend (last 5 periods)

RevenueOperatingNet Income

1707.7億円

1280.8億円

853.9億円

426.9億円

Rev: 1374.8億円Op: 329.5億円NI: 249.9億円

Rev: 1441.8億円Op: 300.5億円NI: 228.1億円

Rev: 1482.5億円Op: 332.9億円NI: 258.5億円

Rev: 1602.3億円Op: 354.5億円NI: 325.6億円

Rev: 1707.7億円Op: 355億円NI: 297.2億円

2022/FY2023/FY2024/FY2025/FY2026/FY

Full-Year Progress

FY2027 Q1

Net Income33.4%

Revenue Progress490.700M

Revenue Forecast200000M

Net Income Progress101.100M

Net Income Forecast30300M

Income Statement Details

Unit: JPY

Unlock Long-Term Financial Data

Your current plan allows viewing financial data for the latest 1 year (annual only). Upgrade to the Standard Plan to view up to 3 years (including quarterly data), or the Premium Plan to access all historical data.

Standard Plan Premium Plan